KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Long-Term Investments (2016 - 2020)

Inovio Pharmaceuticals (INO) has disclosed Long-Term Investments for 11 consecutive years, with $434387.0 as the latest value for Q4 2020.

  • Quarterly Long-Term Investments changed N/A to $434387.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $434387.0 through Dec 2020, changed N/A year-over-year, with the annual reading at $434387.0 for FY2020, N/A changed from the prior year.
  • Long-Term Investments hit $434387.0 in Q4 2020 for Inovio Pharmaceuticals, down from $957567.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $22.4 million in Q1 2016 to a low of $434387.0 in Q4 2020.
  • Historically, Long-Term Investments has averaged $10.6 million across 5 years, with a median of $9.1 million in 2017.
  • Biggest five-year swings in Long-Term Investments: surged 23250.49% in 2016 and later tumbled 57.72% in 2017.
  • Year by year, Long-Term Investments stood at $16.1 million in 2016, then tumbled by 43.5% to $9.1 million in 2017, then decreased by 29.63% to $6.4 million in 2018, then fell by 0.9% to $6.3 million in 2019, then plummeted by 93.13% to $434387.0 in 2020.
  • Business Quant data shows Long-Term Investments for INO at $434387.0 in Q4 2020, $957567.0 in Q3 2020, and $2.7 million in Q2 2020.